(RTTNews) - Galectin Therapeutics (GALT) reported results from NAVIGATE clinical trial evaluating belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis cirrhosis and portal ...

Galectin Therapeutics, Inc. announced results from its NAVIGATE trial, which evaluated belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal ...

Galectin Therapeutics (NASDAQ:GALT) lost ~25% in the premarket on Friday after its NAVIGATE clinical trial for lead candidate belapectin failed to reach the main goal in patients with liver ...

Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases ...

Galectin Therapeutics (GALT) announced results from its global clinical trial NAVIGATE evaluating belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis cirrhosis and portal ...

NORCROSS, Ga. - Galectin Therapeutics Inc. (NASDAQ: NASDAQ:GALT), a clinical-stage biotech company with a current market capitalization of $125.52 million, revealed results from its NAVIGATE clinical ...